These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16007203)

  • 21. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
    Deichmann M; Thome M; Benner A; Näher H
    Oncology; 2004; 66(5):411-9. PubMed ID: 15331929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis.
    Boisvert-Adamo K; Aplin AE
    Oncogene; 2006 Aug; 25(35):4848-56. PubMed ID: 16547495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
    Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
    Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
    Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
    Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
    Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.
    Cui Y; Guadagno TM
    Oncogene; 2008 May; 27(22):3122-33. PubMed ID: 18071315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic similarities between Spitz nevus and Spitzoid melanoma in children.
    Gill M; Cohen J; Renwick N; Mones JM; Silvers DN; Celebi JT
    Cancer; 2004 Dec; 101(11):2636-40. PubMed ID: 15503312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis.
    Zhao Y; Zhang Y; Yang Z; Li A; Dong J
    Biochem Biophys Res Commun; 2008 Jun; 370(3):509-13. PubMed ID: 18402768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.
    Cui Y; Borysova MK; Johnson JO; Guadagno TM
    Cancer Res; 2010 Jan; 70(2):675-84. PubMed ID: 20068179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
    Panka DJ; Atkins MB; Mier JW
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2371s-2375s. PubMed ID: 16609061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
    Ugurel S; Thirumaran RK; Bloethner S; Gast A; Sucker A; Mueller-Berghaus J; Rittgen W; Hemminki K; Becker JC; Kumar R; Schadendorf D
    PLoS One; 2007 Feb; 2(2):e236. PubMed ID: 17311103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
    Deichmann M; Thome M; Benner A; Kirschner M; Hassanzadeh J; Kurzen H
    BMC Cancer; 2005 Jun; 5():58. PubMed ID: 15935100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re: Determinants of BRAF mutations in primary melanomas.
    Purdue MP
    J Natl Cancer Inst; 2005 Mar; 97(5):401-2; author reply 402. PubMed ID: 15741578
    [No Abstract]   [Full Text] [Related]  

  • 36. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.
    Abel EV; Aplin AE
    Cancer Res; 2010 Apr; 70(7):2891-900. PubMed ID: 20332228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical role of miR-10b in B-RafV600E dependent anchorage independent growth and invasion of melanoma cells.
    Datar I; Kalpana G; Choi J; Basuroy T; Trumbly R; Chaitanya Arudra SK; McPhee MD; de la Serna I; Yeung KC
    PLoS One; 2019; 14(4):e0204387. PubMed ID: 30995246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [MAP-Kinase pathway abnormalities in melanoma: B-RAF is not the sole cause].
    Dereure O
    Ann Dermatol Venereol; 2012 Oct; 139(10):691-2. PubMed ID: 23122387
    [No Abstract]   [Full Text] [Related]  

  • 39. Models and mechanisms in malignant melanoma.
    Benjamin CL; Melnikova VO; Ananthaswamy HN
    Mol Carcinog; 2007 Aug; 46(8):671-8. PubMed ID: 17570501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B-RAF and melanocytic neoplasia.
    Gill M; Celebi JT
    J Am Acad Dermatol; 2005 Jul; 53(1):108-14. PubMed ID: 15965430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.